Neuropathology of Alzheimer disease: pathognomonic but not pathogenic
- 27 April 2006
- journal article
- review article
- Published by Springer Nature in Acta Neuropathologica
- Vol. 111 (6) , 503-509
Abstract
Neuropathological changes in subjects with dementia are, by definition, end-stage phenomena. While such changes allow case characterization and lend themselves to disease classification and modeling, the lesions themselves are not etiological. This truth would appear to be self-evident, yet the medical and scientific literature suggests otherwise. Indeed it is now customary to view amyloid plaques in Alzheimer disease as primary etiological, neurotoxic lesions and, hence, removing them (e.g., by immunotherapy) is believed to lead to clinical improvement. The foundation for this line of thinking lies in the existence of rare kindreds with mutations in amyloid-β, or mutations believed to be involved in the processing of amyloid-β, and then the extrapolation of the inherited condition to sporadic disease. We believe that this overall construct ignores early events that are more critical to onset and progression of sporadic disease. Likewise, we have studied subjects with sporadic Alzheimer disease, as well as early onset familial Alzheimer disease and Down’s syndrome, over a spectrum of ages, and have found that markers of oxidative stress precede amyloid deposits in all three conditions. Amyloid and neurofibrillary pathology in the Alzheimer brain show a decrease in oxidative stress relative to vulnerable but morphologically intact neurons, suggesting that neurodegenerative lesions are compensatory phenomena, and thus manifestations of cellular adaptation. The pathology of neurodegenerative diseases should be viewed as the end-stage consequence, as opposed to cause, of the disease processes, so that early disease processes that are amenable to intervention can be properly recognized and treated.Keywords
This publication has 65 references indexed in Scilit:
- Presenilin function and γ‐secretase activityJournal of Neurochemistry, 2005
- Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal deathNature, 2004
- Clinical Validity of Aß-Protein Deposition Staging in Brain Aging and Alzheimer DiseaseJournal of Neuropathology & Experimental Neurology, 2001
- Neuronal Oxidative Stress Precedes Amyloid-β Deposition in Down SyndromeJournal of Neuropathology & Experimental Neurology, 2000
- Protein‐Bound AcroleinJournal of Neurochemistry, 1999
- Neuron loss in APP transgenic miceNature, 1998
- Evidence for oxidative stress in Pick disease and corticobasal degenerationBrain Research, 1995
- β-Amyloid of Alzheimer's Disease Induces Reactive Gliosis That Inhibits Axonal OutgrowthExperimental Neurology, 1993
- Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's diseaseNeurology, 1992
- The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)Neurology, 1991